Tebentafusp yielded a favorable 5-year survival rate vs investigator’s choice of therapy in HLA-A*02:01-positive uveal melanoma.

Read for more on the phase 3 IMCgp100-202 study

https://
hubs.li/Q04cPY080

#melsm #Melanoma #AACR26